Islet cell antibodies (ICA)

Islet cell antibodies (ICA) are a heterogeneous group of autoantibodies that target various protein antigens within the pancreatic islets of Langerhans, serving as the hallmark circulating biomarkers for the autoimmune destruction of insulin-producing beta cells. They typically emerge months or even years before the clinical onset of hyperglycemia, and the presence of multiple antibody types is highly predictive of progression to Type 1 diabetes mellitus (T1DM). Historically identified via indirect immunofluorescence on human or primate pancreas sections, the ICA group is now known to comprise several specific autoantibodies, including those directed against glutamate decarboxylase 65 (GAD65), insulinoma-associated protein 2 (IA-2), and zinc transporter 8 (ZnT8). In the clinical and pharmaceutical context, ICAs are primarily used as enrichment biomarkers to identify candidates for preventative immunotherapies, such as the anti-CD3 monoclonal antibody teplizumab, which is approved to delay the onset of symptomatic T1DM in high-risk individuals. While these antibodies are generally considered markers of an underlying T-cell-mediated immune attack rather than the primary effectors of cell death, recent evidence suggests that certain monoclonal autoantibodies within this class may directly impair islet secretory function through the inhibition of mitochondrial energetics. Additionally, ICAs are critical for the diagnosis of latent autoimmune diabetes in adults (LADA), where they predict rapid progression to insulin dependency in patients initially presenting with a type 2 phenotype.

Other names

Islet autoantibodiesIslet cell cytoplasmic autoantibodiesPancreatic islet cell antibodiesDiabetes-associated autoantibodies

These antibodies serve as clinical biomarkers for patient selection and disease staging rather than primary therapeutic targets; drugs like teplizumab modulate the T-cell-mediated immune response associated with the presence of these biomarkers.